Ascletis Pharma
-
First subject dosed with Gannex’s FXR Agonist ASC42 in US Phase I trial
ASC42 is an in-house developed,novel non-steroidal, selective and potent FXR agonist Gannex, a wholly-owned company of Ascletis Pharma and fully…
Read More »